EdiPro Pharmaceutical
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
EdiPro Pharmaceutical - overview
Established
2022
Location
Chengdu, Sichuan, China
Primary Industry
Biotechnology
About
Based in Sichuan, China and founded in 2022, Chengdu Qianhua Hesheng Pharmaceutical Technology Co. , Ltd. , dba EdiPro Pharmaceutical, is dedicated to building an innovative drug platform that develops novel therapeutics for major diseases and rare genetic disorders. The company was founded by Dr.
Shixian Lin, a professor and doctoral supervisor at the Institute of Life Sciences, Zhejiang University. In September 2026, EdiPro Pharmaceutical closed a round of Pre-series A funding led by Tao Capital with participation from Chengdu Science and Technology Venture Capital Group. EdiPro Pharmaceutical focuses on the development of long-acting peptides, cyclic peptides and antibody-peptide conjugates. leveraging a synthetic biology platform powered by its self-developed chimeric translation system, targeting major chronic metabolic diseases, as well as genetic diseases caused by nonsense mutations.
The company generates revenue from developing novel peptide and protein-based drugs. The company will primarily use the Pre-series A funding to refine the proprietary technology platform and to conduct preclinical studies on existing candidate molecules.
Current Investors
Chengdu Science and Technology Venture Capital Group, Tao Capital, Casstar Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy
Verticals
HealthTech
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
EdiPro Pharmaceutical - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Unspecified Round | Completed | EdiPro Pharmaceutical | - | ||||||||
| Angel | Completed | EdiPro Pharmaceutical | - |
Displaying 1 - 2 of 2
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.